VCC Stock Overview Does not have significant operations. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Fresh Tracks Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Fresh Tracks Therapeutics Historical stock prices Current Share Price US$0.73 52 Week High US$0.96 52 Week Low US$0.44 Beta 0.49 1 Month Change 0% 3 Month Change -1.48% 1 Year Change 5.04% 3 Year Change -98.45% 5 Year Change n/a Change since IPO -99.56%
Recent News & Updates
Fresh Tracks Therapeutics, Inc. Files Form 15 Mar 19
Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index Dec 21 Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index Dec 20
Fresh Tracks Therapeutics Announces Its Common Stock to Be Suspended from Trading on Nasdaq At Open of Business on December 19, 2023 Dec 18
Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq Oct 15
Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq Oct 14 See more updates
Fresh Tracks Therapeutics, Inc. Files Form 15 Mar 19
Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index Dec 21 Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index Dec 20
Fresh Tracks Therapeutics Announces Its Common Stock to Be Suspended from Trading on Nasdaq At Open of Business on December 19, 2023 Dec 18
Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq Oct 15
Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq Oct 14 Fresh Tracks Therapeutics, Inc. Announces Executive Changes
New minor risk - Revenue size Aug 14
Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.43 loss in 2Q 2022) Aug 13
Fresh Tracks Therapeutics, Inc. Announces Resignation of Robert B. Brown from the Board of Directors, Effective Immediately Jul 26
First quarter 2023 earnings released: US$1.14 loss per share (vs US$3.55 loss in 1Q 2022) May 12
Full year 2022 earnings released: US$7.52 loss per share (vs US$22.12 loss in FY 2021) Apr 02
Fresh Tracks Therapeutics, Inc. Announces Executive Changes, Effective February 1, 2023 Jan 28
Fresh Tracks Therapeutics, Inc. Announces Publication of Preclinical Data for FRTX-02 Jan 12
Third quarter 2022 earnings released: US$2.07 loss per share (vs US$7.15 loss in 3Q 2021) Nov 16
Insufficient new directors Nov 16
Fresh Tracks Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 04
Fresh Tracks Therapeutics Appoints Deepak Chadha to the Additional Position of Chief Operating Officer Sep 23
Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of Dyrk1a Inhibitor FRTX-02 Sep 14
Insufficient new directors Sep 02
Brickell Biotech Receives Notice from the Nasdaq Stock Market in Relation to Non-Compliance with the Independent Director and Audit Committee Requirements Aug 25
Second quarter 2022 earnings released: US$0.01 loss per share (vs US$7.29 loss in 2Q 2021) Aug 13
Brickell Biotech, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 03
Brickell Biotech, Inc. Announces Resignation of Dennison T. Veru from the Board of Directors Jul 30
Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement Jul 21
Brickell Biotech Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market Jun 16
Brickell Biotech, Inc. Announces Executive Changes Jun 09
Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02 May 20
First quarter 2022 earnings released: US$0.079 loss per share (vs US$0.15 loss in 1Q 2021) May 14
Brickell Biotech, Inc. to Report Q1, 2022 Results on May 12, 2022 May 06
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 16
Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2020) Nov 11
Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.43 loss in 2Q 2020) Aug 14
Co-Founder & Chairman of the Board recently bought €113k worth of stock Jul 29
Brickell Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $7 million. Jul 24
Brickell Biotech, Inc. Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis Jun 30
Brickell Biotech Announces Initiation of A Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by Its Development Partner, Kaken Pharmaceutical in Japan Jun 25
Brickell Biotech Receives A Notice from Listing Qualifications Department of Nasdaq Stock Market Jun 19
Brickell Biotech, Inc. Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology Jun 02
First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.45 loss in 1Q 2020) May 16
Forecast to breakeven in 2025 May 16
Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis Apr 29
CEO & Director recently bought €99k worth of stock Mar 18
Brickell Biotech, Inc., Annual General Meeting, Apr 19, 2021 Mar 16
Full year 2020 earnings released: US$0.85 loss per share (vs US$4.50 loss in FY 2019) Mar 10
Revenue misses expectations Mar 10
Brickell Biotech, Inc. to Report Q4, 2020 Results on Mar 09, 2021 Feb 24
New 90-day high: €1.36 Feb 10
Brickell Biotech, Inc. Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (Ecclock®) Jan 21
New 90-day high: €0.90 Jan 10
Brickell Biotech, Inc. Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study Dec 10
Brickell Biotech, Inc. Announces Management Changes Nov 25
Third quarter 2020 earnings released: US$0.15 loss per share Nov 14
Brickell Biotech, Inc. to Report Q3, 2020 Results on Nov 12, 2020 Oct 30
New 90-day high: €0.91 Oct 10
Brickell Biotech, Inc. Announces Initiation of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis Oct 07
Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis Sep 26
New 90-day low - €0.65 Sep 08
New 90-day low - €0.67 Aug 20
First half earnings released Aug 14
Brickell Biotech, Inc. to Report Q2, 2020 Results on Aug 12, 2020 Aug 04 Shareholder Returns VCC DE Biotechs DE Market 7D 0% 2.4% -0.4% 1Y 5.0% -10.2% 7.9%
See full shareholder returns
Return vs Market: VCC underperformed the German Market which returned 6.2% over the past year.
Price Volatility Is VCC's price volatile compared to industry and market? VCC volatility VCC Average Weekly Movement n/a Biotechs Industry Average Movement 7.3% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.1% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: VCC has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine VCC's volatility change over the past year.
About the Company Founded Employees CEO Website 2009 13 Bert Marchio ir.frtx.com
Fresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops FRTX-02 (BBI-02), an oral DYRK1A inhibitor that is completed Phase 1 clinical trials for the treatment of autoimmune and inflammatory diseases; FRTX-10 (BBI-10), a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases; and FRTX-03, a topical DYRK1A inhibitor for the treatment of mild-to-moderate skin conditions, as well as next-generation kinase inhibitors. Fresh Tracks Therapeutics, Inc. has license and collaboration agreements with Carna Biosciences, Inc., and Voronoi Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022.
Show more Fresh Tracks Therapeutics, Inc. Fundamentals Summary How do Fresh Tracks Therapeutics's earnings and revenue compare to its market cap? VCC fundamental statistics Market cap €4.95m Earnings (TTM ) -€5.24m Revenue (TTM ) €7.37m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) VCC income statement (TTM ) Revenue US$8.01m Cost of Revenue US$3.18m Gross Profit US$4.82m Other Expenses US$10.52m Earnings -US$5.69m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/03/18 10:30 End of Day Share Price 2023/12/20 00:00 Earnings 2023/12/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Fresh Tracks Therapeutics, Inc. is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Raghuram Selvaraju H.C. Wainwright & Co. Thomas Flaten Lake Street Capital Markets, LLC Leland Gershell Oppenheimer & Co. Inc.
Show 1 more analysts 
